Joint pain and swelling, skin rash, fatigue and fever are often the primary symptoms of systemic lupus erythematosus (SLE), or lupus, but people with this autoimmune condition face a variety of health challenges that affect other organs, including the heart and lungs. Between 30% to 50% of those diagnosed with lupus will develop kidney disease, also known as lupus nephritis, within the first six months to three years of their condition.
In people with lupus, the immune system mistakenly regards its own tissues as foreign substances, setting off a response that leads to tissue inflammation. In otherwise healthy people, inflammation is a normal and temporary part of the immune response. However, in a person with SLE or other types of autoimmune disease, inflammation can become chronic, resulting in damage to joints or organs.
Although autoimmune diseases like lupus can affect all parts of the body, the kidneys may be particularly vulnerable to damage as structures called immune complexes (a combination of an antibody and the ostensibly “foreign material” it is combating) develop and deposit in the kidneys. Once there, they cause both inflammation and alterations in the anatomy of the kidney that result in the loss of protein and/or blood cells in the urine. Of note, each kidney is composed of about 1 million functional units, called nephrons. Each nephron is made of a glomerulus (glomeruli in plural) where the blood is filtered and waste products are excreted as urine. The vessels in the glomerulus that filter waste out of the blood are porous and permit the immune complexes to enter the kidney tissues and cause kidney inflammation (nephritis).
Signs of lupus nephritis may include:
You may not experience any symptoms, however, so a urine test is needed. It is crucial to have your doctor rule out other causes such as kidney stones or a urinary tract infection before considering the diagnosis of nephritis.
For reasons that are not yet fully understood, women develop lupus far more frequently than do men (at a ratio of 9:1) and women of African, Asian and Hispanic descent are at greater risk than their Caucasian counterparts, which suggests a genetic cause. The disease usually occurs during the reproductive years. Similarly, lupus nephritis is seen more frequently in women.
Moreover, lupus nephritis usually develops in people with more severe forms of lupus.
In addition to conducting a thorough physical examination and patient history, doctors use a wide range of tests to assess kidney function. These include measuring creatinine – a waste product related to normal tissue breakdown, as well as levels of certain antibodies and other proteins in the blood and urine. The presence of high levels of anti-DNA antibodies, and lower than normal levels of proteins called Complement 3 and Complement 4 not only help to confirm a diagnosis of lupus but also appear to indicate an increased risk of developing lupus nephritis.
Below is a comprehensive list of additional tests that rheumatologists and other physicians may review when assessing how lupus nephritis and its treatment may be affecting other systems and organs:
Other Important Tests:
Additional tests, such as a renal (kidney) ultrasound, may be needed to exclude other kidney problems that may need a different treatment than lupus nephritis. Before beginning treatment, it is very important to determine that the patient’s kidney problems are being caused by lupus nephritis and not by another condition such as an infection or an obstruction like a kidney stone.
If the physician suspects that lupus nephritis is causing the symptoms and abnormal laboratory results, he or she will often also recommend a biopsy. In this procedure, which is usually performed by a nephrologist using a special needle under ultrasound or other radiographic guidance, a small piece of tissue is removed from the kidney. Biopsies reveal whether any changes have occurred in the cells of the kidney and whether there is any scarring present. [Figures 1A and 1B] Information gathered with a biopsy is an important tool in determining the course of treatment.
Figure 1A (left): Kidney biopsy showing a normal glomerulus.
Figure 1B (right): Kidney biopsy from a patient with class IV lupus nephritis showing a glomerulus
with narrowing/closing of the capillaries (small blood vessel) from an abnormal increase of cells within those vessels.
Lupus nephritis is diagnosed according to the 2003 International Society of Nephrology/Renal Pathology Society (ISN/RPS) classification of lupus nephritis:
Both Class I and Class II are mild forms of the disease that do not require treatment.
Class III and Class IV are serious forms of the disease, with the two types of Class IV being more aggressive than class III.
When Class V occurs by itself, it can take two forms depending on whether the individual has nephrotic proteinuria (the presence of high levels of protein in the urine) or non-nephrotic proteinuria.
In the case of classes III and IV, the biopsy will also indicate the proportion of glomeruli with inflammation (active) and with scar tissue (sclerotic). The presence of more aggressive forms of inflammation such as “crescents” and “fibrinoid necrosis” will also be indicated.
In all classes, the biopsy comments on the presence, type, and degree of tubular, interstitial (the tissue between kidney units) and vascular involvement.
If a person is found to have Class VI disease, or advanced sclerosing lupus nephritis, the kidney contains only scar tissue without active inflammation, and therefore aggressive treatment with immunosuppressive drugs is not indicated. Patients with this type of lupus nephritis will not benefit from medication and are started on dialysis.
People with the more severe forms of lupus nephritis, classes III, IV and V (with nephrotic proteinuria), need to be started on an aggressive course of treatment that is also referred to as induction therapy, since the goal is to induce a remission of the inflammation and related symptoms. During induction therapy, immunosuppressive drugs are administered at high doses. The duration of induction therapy can range from three months to one year. A key point here is to start induction therapy as soon as possible without losing time, in order to minimize loss of kidney tissue from the inflammation. “Time is kidney,” as many doctors say.
As the condition improves, the patient switches to maintenance therapy, in which a lower dose of the drug or drugs is administered. Maintenance therapy continues for at least two years, though the optimal duration is not known yet.
Because immunosuppressive agents are powerful drugs with the potential for serious side effects, the rheumatologist strives to taper their use as soon as the condition allows.
Immunosuppressive agents include:
Adjunctive therapy that addresses other disease-related concerns may include one or more of the following, depending on the individual case and if there are no contraindications:
Initially, some people with very severe lupus nephritis may need to be hospitalized while receiving treatment. This is done to ensure that any complications of the disease or treatment can be addressed promptly. However, many people with lupus nephritis are able to receive specific treatment including therapeutic infusions on an out-patient basis.
Treatment for lupus nephritis can be complicated. Both lupus itself and the drugs taken to manage the disease can put the patient at greater risk of infection, cardiovascular disease, risk of stroke, osteoporosis, and weight gain. Glucocorticoid (steroid) therapy alone is associated with many adverse effects such as weight gain, osteoporosis, and osteonecrosis (bone damage that may lead to severe arthritis of the hip and need for surgery).
The goal is to control the disease as quickly as possible, and then reduce the dose of medications given, to limit side effects. Fortunately, younger patients usually tolerate immunosuppressive drugs better, and lupus primarily affects this younger population. Many patients show rapid improvement with induction therapy.
Unfortunately, people who are successfully treated for lupus nephritis remain at risk of recurrence for the condition. Therefore, regular monitoring of kidney function is essential, especially since the early signs of recurrence may only be detectable with laboratory tests.
People undergoing treatment for lupus nephritis are also advised to follow various guidelines regarding diet, nutritional supplements, and over-the-counter drugs.
In addition to physical challenges, a diagnosis of lupus nephritis can also take a psychological toll. For those having difficulty coping, family support and social work services may help.
If lupus nephritis is active, pregnancy is not just inadvisable, but can be life-threatening. However, in cases where treatment results in a period of quiescence or inactivity for six months, without much kidney damage, and with careful adjustment of medications, a safe pregnancy is the rule. Patients who undergo successful transplants may also be able to proceed with a safe pregnancy.
Timely and aggressive treatment results in considerable improvement or complete remission in many people, but treatment is not yet optimal for all patients. Those who do not respond to conventional treatment may be eligible for clinical studies of newer agents. At the HSS Lupus and APS Center of Excellence, people with lupus nephritis benefit from multidisciplinary care from a team of rheumatologists, nephrologists, pathologists and other specialists, an on-site infusion service, social work and other support services, all in one location.
Many of the Center’s faculty members are engaged in clinical research designed to improve treatment outcomes. Researchers and physicians at HSS and across the country continue to evaluate the possible role of other medications to effectively treat lupus nephritis and minimize the risk of side effects.
Please visit our Lupus Nephritis Program page for more information.
If you would like more information about the treatment of lupus nephritis at HSS, please request an appointment or call 1.877.606.1555.
We thank our trusted colleague, Dr. Surya V. Seshan, Professor of Clinical Pathology and Laboratory Medicine at Weill Cornell Medicine, for her kind provision of the kidney biopsy pictures used in this article and for her helpful comments.
Clinical Research Coordinator, Hospital for Special Surgery